Misc Sierra New Engine 18-0693 Parts Other Trolling Motors & Components


  1. Home
  2. Misc Sierra New Engine 18-0693 Parts
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
New Sierra Misc Engine Parts 18-0693
Condition: New Manufacturer Part Number:

sie 0693

mpn: sie 0693 Brand:

sierra

Warranty: 1 year UPC:

808282303969

published on tue nov 09 2021

Misc Sierra New Engine 18-0693 Parts Other Trolling Motors & Components

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

Misc Sierra New Engine 18-0693 Parts Other Trolling Motors & Components

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.

509
1.2k
EVGENIA.RU RSS